Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
ID: 351096Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351096

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-017.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" through the Small Business Innovation Research (SBIR) cooperative agreement mechanism. This initiative aims to support the development of automated, miniaturized tissue chip platforms that enhance microphysiological systems (MPS) for improved drug discovery and regulatory assessments, with a focus on creating portable systems that maintain 3D tissue constructs and integrate real-time monitoring technologies. The program is significant in advancing innovative in vitro methods that can potentially replace traditional animal testing in biomedical research, aligning with current regulatory trends favoring alternative assessment methods. Interested small businesses can apply for a total funding commitment of up to $2.15 million, with applications due by January 22, 2024, and the earliest project start date anticipated for February 22, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-TR-23-017-Full-Announcement.html
    RFA-TR-23-017.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS), announces the Miniaturization and Automation of Tissue Chip Systems (MATChS) funding opportunity. This initiative aims to enhance microphysiological systems (MPS) by developing automated, miniaturized tissue chip platforms to improve drug discovery and regulatory assessments. Funding through the Small Business Innovation Research (SBIR) cooperative agreements (U43/U44) supports projects that create portable systems to maintain 3D tissue constructs and integrate real-time monitoring technologies. Key details include a commitment of up to $2.15 million to fund two Phase I projects and one Phase II project. Applications are due by January 22, 2024, and the earliest start date is February 22, 2024. The opportunity seeks to facilitate collaboration between small business concerns and NIH, ensuring milestone-driven progress and commercialization pathways. Applicants must adhere to specific requirements outlined in the application guide, ensuring compliance with NIH standards. This program represents a significant push towards innovative in vitro methods that can replace traditional animal testing in biomedical research, aligning with current regulatory trends favoring alternative assessment methods.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at supporting Small Business Technology Transfer (STTR) applications. This initiative seeks to enhance microphysiological systems that replicate organ functions, focusing on the development of compact, automated systems for real-time analysis of tissue health to improve drug discovery and precision medicine. Eligible U.S.-based small businesses can apply for funding of up to $2.15 million for Phase I and Phase II awards, with proposals required to demonstrate innovation, a clear commercialization strategy, and collaboration with NIH staff. Interested applicants should refer to the full announcement available at NIH Grants and note that the application deadline is February 23, 2026.
    Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening," aimed at developing and validating advanced 3-D tissue models for drug efficacy testing. This initiative seeks to create non-animal models that accurately mimic the physiological properties of human tissues, thereby enhancing the predictive accuracy of drug screening processes. With an estimated total program funding of $1,600,000 and the expectation of awarding two grants, interested applicants are encouraged to utilize the resources available at the NCATS 3-D Bioprinting laboratory. The application process is open to various eligible entities, excluding non-domestic applicants, with a submission deadline anticipated by June 16, 2026. For further inquiries, potential applicants can contact Dobrila D. Rudnicki, Ph.D., at dobrila.rudnicki@nih.gov or by phone at 240-535-6621.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects that contribute to the field, although applications are not currently being solicited. With an estimated total program funding of $400,000, interested applicants should prepare for the upcoming Notice of Funding Opportunity (NOFO), with key dates including an estimated synopsis post date of August 1, 2025, and a close date of October 21, 2025. For further inquiries, potential applicants can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
    Selective Precision Targeting (SPoT)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled Selective Precision Targeting (SPoT) aimed at advancing therapeutic drug delivery systems to specific hard-to-reach locations within the human body. This initiative seeks to optimize the targeting of nanoparticle therapeutics, assess biodistribution and off-target effects, provide evidence of functional cargo activity, and determine the optimal route of administration using microphysiological systems. With an estimated total program funding of $1.5 million and the expectation of awarding five grants, eligible small businesses are encouraged to apply. Interested applicants can reach out to Dr. Passley Hargrove-Grimes at passley.hargrove@nih.gov or by phone at 240-485-4149, with proposals due by February 17, 2026, and project start anticipated on January 18, 2027.
    Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)." This funding aims to support small businesses in developing, characterizing, or improving research models related to human health and diseases, as well as creating new approach methodologies (NAMs) that enhance the accessibility and translational value of experimental research models. The initiative is crucial for advancing biomedical research and ensuring that developed resources are broadly applicable across multiple NIH Institutes or Centers. The estimated total program funding is $5 million, with approximately six awards expected. Interested applicants should prepare to submit their proposals by January 25, 2026, with the anticipated award date set for October 1, 2026. For further inquiries, contact Sige Zou, PhD, at 301-435-0749 or via email at sige.zou@nih.gov.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the Animal and Biological Material Resource Centers under the P40 grant mechanism, aimed at supporting projects that develop and maintain animal models and related biological resources. This initiative seeks to enhance the scientific rigor and reproducibility of biomedical research by providing accessible resources, including special colonies of laboratory animals, informatics tools, and new approach methodologies (NAMs) that complement traditional animal-based research. With an estimated total program funding of $1,300,000 and the expectation of awarding two grants, interested small businesses should prepare for the application process, which will open in December 2025, with submissions due by February 2026. For further inquiries, potential applicants can contact Oleg Mirochnitchenko, PhD, at Oleg.mirochnitchenko@nih.gov or by phone at 301-435-0748.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) aimed at advancing research in the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate complex nervous system physiology. This funding opportunity, under the R01 Research Project Grant mechanism, encourages innovative applications that focus on enhancing existing technologies and creating sophisticated models for studying the nervous system's development, function, and aging, while explicitly excluding clinical trial projects. Eligible applicants include a diverse range of organizations, such as educational institutions and community-based organizations, with no specific budget limits as long as costs align with the proposed research. Interested parties should note that the application submission period opens on January 3, 2025, with a closing date of January 7, 2026, and are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.